Journal of Oncology Pharmacy Practice

Papers
(The H4-Index of Journal of Oncology Pharmacy Practice is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients35
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant17
A room of errors simulation to improve pharmacy operators’ knowledge of cytotoxic drug production14
Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center14
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer14
Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient14
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients12
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities12
Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer12
Pharmacists’ practices and views regarding management of sexual health in patients with cancer12
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy11
Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma11
Corrigendum to A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”11
Post COVID availability of oncology drugs – Is this the new normal on both sides of the Atlantic?11
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma11
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients11
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors11
0.071142911911011